Lupus drug benlysta proves safe and effective in large Real-World trial
NCT ID NCT03370263
First seen Feb 01, 2026 · Last updated Jun 16, 2026 · Updated 17 times
Summary
This study looked at the long-term safety and effectiveness of Benlysta, a medication for systemic lupus erythematosus (SLE), in over 1,500 patients in everyday medical practice. Researchers tracked participants for 52 weeks, monitoring side effects, disease activity, and quality of life. The goal was to gather real-world data to ensure the drug is used properly and safely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Hiroshima, 730-0001, Japan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.